(VIANEWS) – The NASDAQ ended the session with FibroGen rising 9.22% to $23.58 on Tuesday, after two successive sessions in a row of losses. NASDAQ rose 1.67% to $11,584.55, following the last session’s downward trend on what was an all-around positive trend exchanging session today.
FibroGen’s last close was $21.59, 4.6% below its 52-week high of $22.63.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-2.11.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -109.07%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.3%, now sitting on 263.15M for the twelve trailing months.
More news about FibroGen (FGEN).
